Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Parellada
Eduard
E
Clinic Schizophrenia Program, Hospital Clínic de Barcelona, University of Barcelona, CIBERSAM, Spain. eparella@clinic.ub.es
Kouniakis
Filippos
F
Siurkute
Aldona
A
Schreiner
Andreas
A
Don
Liana
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018967:Risperidone / Q000008:administration & dosage* / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*; D016903:Drug Monitoring
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone